{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:03Z","timestamp":1740144063483,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40261-023-01317-z","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T10:01:49Z","timestamp":1699351309000},"page":"927-937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0770-6172","authenticated-orcid":false,"given":"Kentaro","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Kosakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ioji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"1317_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4239\/wjd.v7.i17.354","volume":"7","author":"JJ Mar\u00edn-Pe\u00f1alver","year":"2016","unstructured":"Mar\u00edn-Pe\u00f1alver JJ, Mart\u00edn-Tim\u00f3n I, Sevillano-Collantes C, del Ca\u00f1izo-G\u00f3mez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7:354\u20135. https:\/\/doi.org\/10.4239\/wjd.v7.i17.354.","journal-title":"World J Diabetes"},{"issue":"Suppl. 1","key":"1317_CR2","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, on behalf of the American Diabetes Association, et al. Pharmacological approaches to glycemic treatment: standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S140\u201357. https:\/\/doi.org\/10.2337\/dc23-S009.","journal-title":"Diabetes Care"},{"key":"1317_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4093\/dmj.2011.35.3.300","volume":"13","author":"R Bouchi","year":"2022","unstructured":"Bouchi R, Sugiyama T, Goto A, Imai K, Ihara-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13:280\u201391. https:\/\/doi.org\/10.4093\/dmj.2011.35.3.300.","journal-title":"J Diabetes Investig."},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4093\/dmj.2011.35.3.300","volume":"35","author":"SA Kim","year":"2011","unstructured":"Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J. 2011;35:159\u201365. https:\/\/doi.org\/10.4093\/dmj.2011.35.3.300.","journal-title":"Diabetes Metab J"},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.clinthera.2016.01.017","volume":"38","author":"S Sakai","year":"2016","unstructured":"Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther. 2016;38:843\u201362. https:\/\/doi.org\/10.1016\/j.clinthera.2016.01.017.","journal-title":"Clin Ther"},{"key":"1317_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570\u201381. https:\/\/doi.org\/10.1001\/jama.287.19.2570.","journal-title":"JAMA"},{"key":"1317_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00059-022-05138-2","volume":"47","author":"H Haller","year":"2022","unstructured":"Haller H. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes: lessons from the FIGARO-DKD trial. Herz. 2022;47:401\u20139. https:\/\/doi.org\/10.1007\/s00059-022-05138-2.","journal-title":"Herz"},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/nu12092509","volume":"12","author":"V Cassano","year":"2020","unstructured":"Cassano V, Crescibene D, Hribal ML, Pelaia C, Armentaro G, Magurno M, et al. Uric acid and vascular damage in essential hypertension: role of insulin resistance. Nutrients. 2020;12:2509. https:\/\/doi.org\/10.3390\/nu12092509.","journal-title":"Nutrients"},{"key":"1317_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331. https:\/\/doi.org\/10.1210\/jc.2011-2260.","journal-title":"J Clin Endocrinol Metab"},{"key":"1317_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1291\/hypres.31.1559","volume":"31","author":"R Kawamoto","year":"2008","unstructured":"Kawamoto R, Kohara K, Tabara Y, Miki T, Ohtsuka N, Kusunoki T, et al. An association between body mass index and estimated glomerular filtration rate. Hypertens Res. 2008;31:1559\u201364. https:\/\/doi.org\/10.1291\/hypres.31.1559.","journal-title":"Hypertens Res"},{"key":"1317_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1507\/endocrj.EJ15-0749","volume":"63","author":"C Yamamoto","year":"2016","unstructured":"Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J. 2016;63:589\u201396. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0749.","journal-title":"Endocr J"},{"key":"1317_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hepr.13236","volume":"49","author":"Y Sumida","year":"2019","unstructured":"Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (lead trial). Hepatol Res. 2019;49:64\u20137. https:\/\/doi.org\/10.1111\/hepr.13236.","journal-title":"Hepatol Res"},{"key":"1317_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"1317_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, CVD-REAL Investigators and Study Group, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136:249\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029190.","journal-title":"Circulation"},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33.","journal-title":"BMC Gastroenterol"},{"key":"1317_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104\u201312. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1317_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jdi.12471","volume":"7","author":"A Kashiwagi","year":"2016","unstructured":"Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, et al. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: a subgroup analysis of five randomized clinical trials. J Diabetes Investig. 2016;7:544\u201354. https:\/\/doi.org\/10.1111\/jdi.12471.","journal-title":"J Diabetes Investig."},{"key":"1317_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/dom.14288","volume":"23","author":"M Kitazawa","year":"2021","unstructured":"Kitazawa M, Katagiri T, Suzuki H, Matsunaga S, Yamada MH, Ikarashi T, et al. A52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study. Diabetes Obes Metab. 2021;23:811\u201321. https:\/\/doi.org\/10.1111\/dom.14288.","journal-title":"Diabetes Obes Metab"},{"key":"1317_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109037","volume":"180","author":"C Son","year":"2021","unstructured":"Son C, Makino H, Kasahara M, Tanaka T, Nishimura K, Taneda S, et al. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2021;180: 109037. https:\/\/doi.org\/10.1016\/j.diabres.2021.109037.","journal-title":"Diabetes Res Clin Pract"},{"key":"1317_CR20","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508\u201315. https:\/\/doi.org\/10.2337\/dc12-2491.","journal-title":"Diabetes Care"},{"key":"1317_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s12325-019-0895-1","volume":"36","author":"I Nakamura","year":"2019","unstructured":"Nakamura I, Maegawa H, Tobe K, Uno S. Safety and effectiveness of ipragliflozin for type 2 diabetes in Japan: 12-month interim results of the STELLA-LONG TERM Post-marketing surveillance study. Adv Ther. 2019;36:923\u201349. https:\/\/doi.org\/10.1007\/s12325-019-0895-1.","journal-title":"Adv Ther"},{"key":"1317_CR22","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e7","volume":"34","author":"HU Moon","year":"2019","unstructured":"Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The association of adiponectin and visceral fat with insulin resistance and \u03b2-cell dysfunction. J Korean Med Sci. 2019;34: e7. https:\/\/doi.org\/10.3346\/jkms.2019.34.e7.","journal-title":"J Korean Med Sci"},{"key":"1317_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fendo.2019.00080","volume":"10","author":"CF Deacon","year":"2019","unstructured":"Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2019;10:80. https:\/\/doi.org\/10.3389\/fendo.2019.00080.","journal-title":"Front Endocrinol"},{"key":"1317_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.numecd.2006.05.007","volume":"17","author":"DB Panagiotakos","year":"2007","unstructured":"Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis. 2007;17:590\u20137. https:\/\/doi.org\/10.1016\/j.numecd.2006.05.007.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1317_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:591\u2013601. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.005.","journal-title":"Cell Metab"},{"key":"1317_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.diabres.2016.09.025","volume":"122","author":"M Ohara","year":"2016","unstructured":"Ohara M, Fukui T, Ouchi M, Watanabe K, Suzuki T, Yamamoto S, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62\u201370. https:\/\/doi.org\/10.1016\/j.diabres.2016.09.025.","journal-title":"Diabetes Res Clin Pract"},{"key":"1317_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetes patients. J Clin Invest. 2014;124:499\u2013508. https:\/\/doi.org\/10.1172\/JCI72227.","journal-title":"J Clin Invest"},{"key":"1317_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509\u201314. https:\/\/doi.org\/10.1172\/JCI70704.","journal-title":"J Clin Invest"},{"key":"1317_CR29","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","volume":"62","author":"RE Kuhre","year":"2019","unstructured":"Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62:1011\u201323. https:\/\/doi.org\/10.1007\/s00125-019-4849-6.","journal-title":"Diabetologia"},{"key":"1317_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101071","volume":"42","author":"H Chae","year":"2020","unstructured":"Chae H, Augustin R, Gatineau E, Mayoux E, Bensellam M, Antoine N, et al. SGLT2 is not expressed in pancreatic \u03b1- and \u03b2-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. Mol Metab. 2020;42: 101071. https:\/\/doi.org\/10.1016\/j.molmet.2020.101071.","journal-title":"Mol Metab."},{"key":"1317_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1507\/endocrj.EJ20-0366","volume":"68","author":"Y Morita","year":"2021","unstructured":"Morita Y, Ohno H, Kobuke K, Oki K, Yoneda M. Variation in plasma glucagon levels according to obesity status in Japanese Americans with normal glucose tolerance. Endocr J. 2021;68:95\u2013102. https:\/\/doi.org\/10.1507\/endocrj.EJ20-0366.","journal-title":"Endocr J"},{"key":"1317_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1210\/jc.2015-3885","volume":"101","author":"H Manell","year":"2016","unstructured":"Manell H, Staaf J, Manukyan L, Kristinsson H, Cen J, Stenlid R, Ciba I, et al. Altered plasma levels of glucagon, GLP-1 and glicentin during OGTT in adolescents with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2016;101:1181\u20139. https:\/\/doi.org\/10.1210\/jc.2015-3885.","journal-title":"J Clin Endocrinol Metab"},{"key":"1317_CR33","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, CREDENCE Trial Investigators, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"key":"1317_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, DAPA-CKD Trial Committees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"1317_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12851","volume":"10","author":"T Sasaki","year":"2019","unstructured":"Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT Study. J Diabetes Investig. 2019;10:108\u201317. https:\/\/doi.org\/10.1111\/jdi.12851.","journal-title":"J Diabetes Investig."},{"key":"1317_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.ajkd.2018.02.362","volume":"72","author":"HR Yun","year":"2018","unstructured":"Yun HR, Kim H, Park JT, Chang TI, Yoo TH, Kang SW, Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD), et al. Investigators Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis. 2018;72:400\u201310. https:\/\/doi.org\/10.1053\/j.ajkd.2018.02.362.","journal-title":"Am J Kidney Dis"},{"key":"1317_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/HJH.0b013e3283418875","volume":"29","author":"NE Straznicky","year":"2011","unstructured":"Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens. 2011;29:553\u201364. https:\/\/doi.org\/10.1097\/HJH.0b013e3283418875.","journal-title":"J Hypertens"},{"key":"1317_CR38","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/01.asn.0000068462.38661.89","volume":"14","author":"A Chagnac","year":"2003","unstructured":"Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephorol. 2003;14:1480\u20136. https:\/\/doi.org\/10.1097\/01.asn.0000068462.38661.89.","journal-title":"J Am Soc Nephorol"},{"key":"1317_CR39","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1523-1755.2004.00582.x","volume":"65","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kid Int. 2004;65:1870\u20136. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00582.x.","journal-title":"Kid Int."},{"key":"1317_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/ajkd.2003.50039","volume":"41","author":"E Morales","year":"2003","unstructured":"Morales E, Valero MA, Le\u00f3n M, Hern\u00e1ndez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319\u201327. https:\/\/doi.org\/10.1053\/ajkd.2003.50039.","journal-title":"Am J Kidney Dis"},{"key":"1317_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13340-020-00444-8","volume":"11","author":"M Kitada","year":"2020","unstructured":"Kitada M, Hirano T, Koya D. Signifcance of SGLT2 inhibitors: Lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetol Int. 2020;11:245\u201351. https:\/\/doi.org\/10.1007\/s13340-020-00444-8.","journal-title":"Diabetol Int"},{"key":"1317_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, et al. SGLT2 inhibition mediates protection from diabetes kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32:404\u201319. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.020.","journal-title":"Cell Metab"},{"key":"1317_CR43","doi-asserted-by":"publisher","first-page":"11463","DOI":"10.3390\/ijms222111463","volume":"22","author":"M Koike","year":"2021","unstructured":"Koike M, Saito H, Kohno G, Takubo M, Watanabe K, Ishihara H. Effects of GLP-1RA and SGLT2i, alone or in combination, on mouse models of type 2 diabetes representing different disease stages. Int J Mol Sci. 2021;22:11463. https:\/\/doi.org\/10.3390\/ijms222111463.","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01317-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01317-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01317-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:40:21Z","timestamp":1701920421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01317-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01317-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"5 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Astellas Pharma, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kentaro Watanabe has received lecture fees from Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, and Novo Nordisc Pharma. Hisamitsu Ishihara has served on the advisory board of Astellas Pharma Inc., has received lecture fees from Astellas Pharma, MSD, Nippon Boehringer Ingelheim, and Novo Nordisc Pharma, and has received grants from Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Eli Lilly, and Daiichi-Sankyo. Susumu Yamaguchia and Yoshinori Kosakai are employees of Astellas Pharma Inc. Tetsuya Ioji has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The study was approved by Council for International Organizations of Medical Sciences International Ethical Guidelines and conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for Good Clinical Practice. The study protocol was approved by the Certified Review Board of Nihon University Itabashi Hospital on 9 April, 2019 (CRB3180013).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants gave their written informed consent for participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design of the work: HI, KW, SY, and YK. Study conduct and data acquisition: KW and HI. Analysis of data: TI. All authors contributed to the data interpretation, drafting, critical review, and revision of the manuscript and approved the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}